MSB 2.17% $1.13 mesoblast limited

Cell Therapy News/Articles, page-4202

  1. mja
    1,342 Posts.
    lightbulb Created with Sketch. 280
    Of note in the Gilead release overnight. If you read the study, hydroxychloroquine has been shown in vitro to reduce remdesivir's efficacy via interfering with remdesivir's mechanism of action. And the results showed a higher reduction in mortality in the patient's on remdesivir alone, versus those commenced on remdesivir while also on hydroxychloroquine.

    I took a large position in Gilead overnight, as I expected the left wing media to be all over it. But it appears they only use headlines and social media for research.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.